Navigation Links
Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension

was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 100,000 associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.

References 1. MacDonald, TM et al. Improved blood pressure control but similar efficacy with Prexige 100 mg od compared to ibuprofen 600 mg tid in hypertensive patients with osteoarthritis: randomised clinical trial. Presented at EULAR 2007 [SAT2620]. 2. MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-774. 3. Singh G, et al. Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis. J Rheumatol 2003;30:714-719. 4. Singh G, Miller JD, Lee FH, et al. Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination Survey. Am J Manag Care 2002 Oct;8(15 Suppl):S383-91. 5. Maetzel A, Li LC, Pencharz J,et al. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis. 2004 Apr;63(4):395-401. 6. Johnson AG, et al. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994;121:289-300. 7. Aw TJ, et al. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005;165:490-496. 8. Morgan TO, et al. Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. Am J Hypertens 2000;13:1161-1167. 9. http://www.who.int/ mip/2003/other_documents/en/globalburdenofdisease.pdf 10. Farkouh M, et al. Comparison of
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:1/7/2009)...y 7 Circassia Ltd, a specialty,bi...tical care, today,announced that following succes...oleroMune(R) anti-allergy technology, the company ...er phase II clinical trial in cat allergy. The,st...0 patients with confirmed,cat allergies, and all ...
(Date:1/6/2009)...ewswire-USNewswire/ -- Sequella, Inc., a clinical-...s of epidemic potential, announced today that SQ10...berculosis (TB), was the first drug approved for e...ract to Dynport Vaccine Company LLC and Quintiles ...al Institute of Allergy and Infectious Diseases (N...
(Date:1/5/2009)...PRNewswire-FirstCall/ -- Micromet, Inc.,(Nasdaq: ...ovel, proprietary,antibodies for the treatment of...ovides an outlook on key events anticipated for th...e an update on its research and development,progr...to 16, 2009: Update on several preclinical BiTE an...
(Date:12/27/2008)...23 Warner Chilcott Limit...ts subsidiaries and Mayne Pharma International Pty...ave filed lawsuits against each of Mutual Pharmace...cals Inc. ("Mylan") and Impax Laboratories, Inc. (...f New Jersey for infringement of Mayne,s U.S. Pate...
Breaking Medicine Technology:Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 3Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Micromet Key Events for 2009 2Micromet Key Events for 2009 3Micromet Key Events for 2009 4Micromet Key Events for 2009 5Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 2Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 3Sticky questions tackled in gecko research 1692 1Sticky questions tackled in gecko research 1692 2American Lung Association Offers Biodiesel Scholarship to Minnesota High School Seniors 8632 1Alegent com Goes Mobile 8628 1Alegent com Goes Mobile 8628 2Nick at Nite Asks Families to Kick a Bad Habit Pick a Good One in 2008 8624 1Nick at Nite Asks Families to Kick a Bad Habit Pick a Good One in 2008 8624 2Nick at Nite Asks Families to Kick a Bad Habit Pick a Good One in 2008 8624 3
... the ASCO Cancer Conference, NORTH HOLLYWOOD, Cali... International Myeloma Foundation (IMF)-supporting...pport for myeloma patients,families, researchers ...up to a Phase 3 multi- national clinical trial sho...roves the probability of,survival by 41%. The foll...
...-Agent Activity Support Development of Panzem(R),N...forme, ROCKVILLE, Md., June 05, 2007 /PRNewswire-F...rmaceutical company developing,therapeutics for th...nnounces the presentation of results of a single-a...ients with glioblastoma,multiforme (GBM). The data...
Other Medicine Technology:Study Shows Velcade Plus Doxil Improves Survival in Previously,Treated Patients With Multiple Myeloma 2Phase 2 Results for EntreMed's Panzem NCD Brain Cancer Study,Presented at ASCO 2Phase 2 Results for EntreMed's Panzem NCD Brain Cancer Study,Presented at ASCO 3Phase 2 Results for EntreMed's Panzem NCD Brain Cancer Study,Presented at ASCO 4
(Date:1/8/2009)...Newswire-FirstCall/ -- Medivation, Inc.,(Nasdaq: ...esident and chief,executive officer, will present...ence on Wednesday, January 14, at 10:00 a.m. Pacif...ancisco. , Dr. Hung will provide an overvie...rams for Dimebon for Alzheimer,s and Huntington,s ...
(Date:1/8/2009)...g traditional risk factors, experts say , ...ular signs -- or "biomarkers" -- of inflammation m...s a person,s risk of stroke, new research says. ,...these markers does not change things much," said s...t the Methodist DeBakey Heart & Vascular Cente...
(Date:1/8/2009)...wswire-FirstCall/ -- Heska Corporation (Nasdaq: ... What: Heska Corporation Invites You to Joi...008 Earnings Conference Call on the Web, Whe..., Where: www.heska.com (click on the Q4 and ... the front page of this website)., How: ...
(Date:1/8/2009)...ter Healthcare Corporation will create a multidisc... entities announced today. , Under the three-yea...ollaboration projects at Northwestern. Funding lev...on, and Baxter will determine specific project fun...Baxter,s diversified business model, activities wi...
Breaking Medicine News(10 mins):Health News:Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference 2Health News:Inflammation Markers May Help Predict Stroke Risk 2Health News:Inflammation Markers May Help Predict Stroke Risk 3Health News:Webcast Alert: Heska Announces Fourth Quarter and Year-End 2008 Earnings Conference Call Webcast 2Health News:Baxter and Northwestern University partner to target new life sciences projects 2
... is the fastest growing disability in the United S...ch up. One out// of every 166 children is diagnose...c cancer, diabetes and AIDS combined. The Autism ... and Training (ASSERT) program at Utah State Unive...
... looking to lose those extra pounds have been told...ill bring about the best results//. Not so, says n...s effective as dieting plus exercise. The key is i...t calories can be lost effectively by either dieta...
...ing to a latest study, blood letting in patients w...f carried out at a young age//. This finding was p...merican Medical Association. Iron deposit in the ...eloping heart ailments. Hence reducing iron from t...
...from Naples, New York who was diagnosed with lung ...enk who is a former Marine// is currently sufferin...ven him a year or at the maximum eighteen months o...his lottery. But the irony that is accompanying th...
Other Medicine News:Health News:Autism Expert Creates Innovative Intervention Program 2Health News:Autism Expert Creates Innovative Intervention Program 3Health News:Shedding Pounds from Diet or Exercise—Take Your Pic 2Health News:Shedding Pounds from Diet or Exercise—Take Your Pic 3
...White Sun light source offers the industry standar...o Kelvin color temperature at a lower price. A uni...Sun to be used with Olympus, Storz, ACMI/Circon an...s light output LED and re-settable bulb timer. The...
...NGAL ELISA Kit is intended for determination of hu...ine), tissue extracts or culture media., NGAL (n...atically increased, especially in urine, as early ... repair processes. NGAL expression in plasma or ur...
...Dual Light Head is clearly the favorite for most s... arms, the dual light heads rotate freely about th...nlimited positioning. Engineered construction prev...es ranging from minimally invasive through trauma ...
... configuration offers all the performance of a maj...ctly for use in Outpatient Settings, Minor Procedu...ng two single lights either side of the OR table i...hen combining Flat Screen LCD Monitors with the li...
Medicine Products: